Why Insilico Medicine matters
Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, raising about $293 million in the year's largest Hong Kong biotech IPO. Its lead drug rentosertib, an AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis, posted positive Phase IIa results published in Nature Medicine in June 2025. On April 28, 2026 it received IND clearance for an inhaled version and said oral Phase III trials remain on track for the second half of 2026.
The numberListed on HKEX (3696) on Dec 30, 2025, raising HK$2.28B (about $293M)
On The All Things AI 100
Listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance.
Quick answers
- What does Insilico Medicine do?
- Generative AI drug discovery company (Pharma.AI) with a clinical pipeline led by the IPF drug rentosertib. Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, raising about $293 million in the year's largest Hong Kong biotech IPO.
- What AI capabilities does Insilico Medicine offer?
- Insilico Medicine offers Pharma.AI for drug discovery teams. PandaOmics ranks disease targets from multi-omics and text data. Chemistry42 generates and evaluates small-molecule structures against those targets. inClinico estimates whether a clinical program is likely to succeed. Pharma users apply these tools to select targets, design candidate molecules, and judge trial risk before larger development spending.
- Why is Insilico Medicine on The All Things AI 100?
- Insilico Medicine is listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance. Listed on HKEX (3696) on Dec 30, 2025, raising HK$2.28B (about $293M).
- Where is Insilico Medicine based, and who owns it?
- Insilico Medicine is based in Cambridge, MA, was founded in 2014 and is public (HKEX: 3696).